DLDel Leary

Del Leary

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Del Leary has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Operational Radiation Safety Considerations During Equine Superficial Radiation Treatment Using Portable X-Ray Devices

    by Ashutosh Singh, Thomas Johnson, Kathryn Wotman, Del Leary

    Veterinary personnel exposure due to scattered x rays, when present during superficial radiation treatment (SRT), was evaluated. Veterinary personnel presence is needed during SRT to minimize the degree of required aesthesia to horses. Animal treatment was simulated, and exposure rates determined for 50, 70, and 100 kV x rays using eight different SRT applicators. Exposure rates at the surface of a solid water phantom (SWP) phantom ranged from 3.9 mR h−1 to 396 mR h−1 for 50 kV, from 41 mR h−1 to 2,880 mR h−1 for 70 kV, and from 235 mR h−1 to 7,500 mR h−1, for 100 kV, respectively. A horse phantom was used to mimic SRT equine ocular treatment creating a spatial exposure field where the directional scatter was measured at 1 m. The minimum distance away from the source to reach < 2 mR h−1 varied with angular position and energy and was lowest for all energies directly behind the x-ray tube. The closest distance before exceeding 2 mR h−1 at 50 kVp was determined to 1.96 m. A worker could stand 1 m behind the x-ray tube at 50 kVp with 0.25 mm lead for 15,106 hours. Typical SRT treatment times for horse eyelid squamous cell carcinoma are less than 5 minutes, and radiation doses to practitioners are expected to be well below local administrative ALARA limits.

  • Open Access

    Investigation of Gastrointestinal Toxicities Associated with Concurrent Abdominal Radiation Therapy and the Tyrosine Kinase Inhibitor Sunitinib in a Mouse Model

    by Amber R. Prebble, Bailey Latka, Braden Burdekin, Del Leary, Mac Harris, Daniel Regan, Mary-Keara Boss

    Tyrosine kinase inhibitors (TKIs) may be combined with radiation therapy (RT) to enhance tumor control; however, increased incidences of gastrointestinal (GI) toxicity have been reported with this combination. We hypothesize that toxicity is due to compromised intestinal healing caused by inhibition of vascular repair and proliferation pathways. This study explores underlying tissue toxicity associated with abdominal RT and concurrent sunitinib in a mouse model. Four groups of CD-1 mice were treated with 12 Gy abdominal RT, oral sunitinib, abdominal RT + sunitinib, or sham treatment. Mice received oral sunitinib or the vehicle via gavage for 14 days. On day 7, mice were irradiated with 12 Gy abdominal RT or sham treated. Mice were euthanized on day 14 and intestinal tract was harvested for semiquantitative histopathologic evaluation and immunohistochemical quantification of proliferation (Ki67) and vascular density (CD31). Non-irradiated groups had stable weights while abdominal irradiation resulted in weight loss, with mice receiving RT + SUN having greater weight loss than mice receiving RT alone. Semiquantitative analysis showed significant increases in inflammation in irradiated groups. The difference in the density of CD31+ cells was significantly increased in RT alone compared to SUN alone. Ki67+ density was not significant. In summary, we identify a lack of angiogenic response in irradiated GI tissues when abdominal RT is combined with a TKI, which may correlate with clinical toxicities seen in canine and human patients receiving combined treatment.

  • Open Access

    Outcome of stereotactic body radiation for treatment of nasal and nasopharyngeal lymphoma in 32 cats

    by Alicja I. Reczynska, Susan M. LaRue, Mary-Keara Boss, Ber-In Lee, Del Leary, Kelsey Pohlmann, Lynn Griffin, Susan Lana, Tiffany Wormhoudt Martin

    Background The safety and efficacy of stereotactic body radiation therapy (SBRT) in the treatment of localized nasal lymphoma in cats has not been described. Hypothesis Stereotactic body radiation therapy with or without adjuvant chemotherapy is an effective and well-tolerated treatment for localized nasal lymphoma in cats. Animals Thirty-two client owned cats referred to Colorado State University for the treatment of nasal lymphoma. Methods Retrospective study of cats treated with SBRT between 2010 and 2020 at Colorado State University. Diagnosis of nasal lymphoma was obtained via cytology or histopathology. Signalment, radiation protocol, concurrent treatments, adverse effects, and survival were recorded. Results Progression free survival was 225 days (95% CI 98–514) and median survival time (MST) was 365 days (95% CI 123–531). No significant difference in survival was identified between cats that received 1 versus greater than 1 fraction (MST 427 vs. 123 days, P = 0.88). Negative prognostic factors included cribriform lysis (MST 121 vs. 876 days, P = 0.0009) and intracalvarial involvement (MST 100 vs. 438 days, P = 0.0007). Disease progression was noted in 38% (12/32), locally in 22% (7/32), and systemically in 16% (5/32). No cats developed acute adverse effects. Ten cats developed late adverse effects: keratitis/keratitis sicca (n = 2), alopecia (n = 4), and leukotrichia (n = 4). Twenty-four cats (75%) had signs consistent with chronic rhinitis. Conclusions SBRT is effective and well tolerated for treating localized nasal lymphoma in cats. Outcomes for cats with lower stage disease (canine modified Adam's stage 3 and lower) are comparable to historic data of cats treated with fractionated radiation therapy.


  • Comparative study of the collapsed cone convolution and Monte Carlo algorithms for radiation therapy planning of canine sinonasal tumors reveals significant dosimetric differences

    by Ber‐In Lee, Mary‐Keara Boss, Susan M. LaRue, Tiffany Martin, Del Leary

    Computer‐based radiation therapy requires high targeting and dosimetric precision. Analytical dosimetric algorithms typically are fast and clinically viable but can have increasing errors near air‐bone interfaces. These are commonly found within dogs undergoing radiation planning for sinonasal cancer. This retrospective methods comparison study is designed to compare the dosimetry of both tumor volumes and organs at risk and quantify the differences between collapsed cone convolution (CCC) and Monte Carlo (MC) algorithms. Canine sinonasal tumor plans were optimized with CCC and then recalculated by MC with identical control points and monitor units. Planning target volume (PTV)air, PTVsoft tissue, and PTVbone were created to analyze the dose discrepancy within the PTV. Thirty imaging sets of dogs were included. Monte Carlo served as the gold standard calculation for the dosimetric comparison. Collapsed cone convolution overestimated the mean dose (Dmean) to PTV and PTVsoft tissue by 0.9% and 0.5%, respectively (both P < 0.001). Collapsed cone convolution overestimated Dmean to PTVbone by 3% (P < 0.001). Collapsed cone convolution underestimated the near‐maximum dose (D2) to PTVair by 1.1% (P < 0.001), and underestimated conformity index and homogeneity index in PTV (both P < 0.001). Mean doses of contralateral and ipsilateral eyes were overestimated by CCC by 1.6% and 1.7%, respectively (both P < 0.001). Near‐maximum doses of skin and brain were overestimated by CCC by 2.2% and 0.7%, respectively (both P < 0.001). As clinical accessibility of Monte Carlo becomes more widespread, dose constraints may need to be re‐evaluated with appropriate plan evaluation and follow‐up.


  • Outcome and prognosis for canine appendicular osteosarcoma treated with stereotactic body radiation therapy in 123 dogs

    by Tiffany Wormhoudt Martin, Lynn Griffin, James Custis, Stewart D. Ryan, Mary Lafferty, Mary‐Keara Boss, Daniel Regan, Sangeeta Rao, Del Leary, Stephen J. Withrow, et al.

    Canine appendicular osteosarcoma is commonly treated with limb amputation; however, limb‐sparing options are frequently desired or necessary for a subset of patients. We evaluated 123 patients and 130 sites treated with stereotactic body radiation therapy (SBRT). Eighty‐two out of 98 dogs (84%) had maximum lameness improvement at a median of 3 weeks for a median of 6 months duration. Histopathologic evaluation of available samples from amputation or necropsy revealed >80% tumor necrosis in 50% of limbs consistent with local disease control. Of evaluable patients, 41% fractured and 21% pursued an amputation after treatment. Fine needle aspirate (n = 52) and needle core biopsy (n = 28) did not result in increased fracture risk compared to those without tumor sampling (n = 50). Median survival time (MST) was 233 days and time to first event was 143 days. Gross tumor volume and planned target volume were significantly inversely associated with survival and tumor location was significantly associated with survival. Dogs with salvage amputation had a significantly longer MST compared to those without (346 vs 202 days; P = .04). The presence of metastatic disease at the time of treatment in 15 dogs did not significantly impact survival time (200 vs 237 days without metastasis; P = .58). Skin side effects correlated significantly with dose with 33% of patients with acute grade 3 effects developing consequential late grade 3 effects. While SBRT improves lameness in most patients, further investigation is needed to identify candidates with minimal early fracture risk prior to initiating therapy.


  • Safety and efficacy of stereotactic body radiation therapy (SBRT) for the treatment of canine thyroid carcinoma

    by Ber‐In Lee, Susan M. LaRue, Bernard Seguin, Lynn Griffin, Amber Prebble, Tiffany Martin, Del Leary, Mary‐Keara Boss

    Thyroid carcinoma develops spontaneously in dogs, with only 25% to 50% of cases amenable to surgery at diagnosis. Local control for unresectable tumours can be provided with external beam radiotherapy. The aim of this retrospective study is to describe the safety and efficacy of stereotactic body radiation therapy (SBRT) for treatment of canine thyroid carcinoma. Twenty‐three dogs met inclusion criteria; median tumour volume before SBRT was 129.9 cm3(range, 2.7‐452.8 cm3). Sixteen patients (70%) had unresectable tumours. Pulmonary metastasis was present or suspected in 10 patients (44%) before SBRT. Patients were prescribed 15 to 40 Gy to targeted tumour volume in one to five fractions. Twenty patients evaluated had overall response rate of 70% (complete response, n = 4; partial response, n = 10). Thirteen out of sixteen (81%) symptomatic patients had clinical improvement within a median time of 16 days (range, 2‐79 days). Median progression free survival (MPFS) was 315 days. Median survival time (MST) was 362 days. Nine patients (39%) had grade 1 acute radiation toxicity. Three patients had grade 1 late radiation toxicity (two leukotrichia and one [4%] with intermittent cough). Responders had significantly longer MPFS (362 vs 90 days; HR 4.3; 95% CI 1.4‐13.5;P= .013) and MST (455 vs 90 days; HR 2.9; 95% CI 1‐8.4;P= .053). Presenting with metastasis was not a significant negative prognostic factor (MST 347 vs 348 days without metastasis;P= .352). SBRT is a safe and effective treatment modality for non‐resectable canine thyroid carcinoma.


    • 1 June 2020
      • Vol. 61  (6) , 638-644

    3D-printed bolus improves dose distribution for veterinary patients treated with photon beam radiation therapy

    by Tiffany Wormhoudt Martin, Mary-Keara Boss, Susan M. LaRue, Del Del Leary

    Commercial bolus is frequently used to increase dose at the patient's surface for superficial radiotherapy; however, uneven surfaces can create air gaps and discrepancies between prescribed and delivered dose. The purpose of this study was to determine if a customizable, 3D-printed bolus would improve dosimetry compared with a commercial bolus. For each patient, a planned bolus was generated within planning software, then created with 3D-printing. The treatment plan was recalculated with each bolus in situ. When evaluating tumor volumes at prescription, the 3D-printed bolus was closer to prescription compared to the commercial bolus. There was a significant difference in air gaps in patients receiving radiotherapy to the head (P < 0.001) but the difference was not significant for air gaps in caudal body sites (P = 0.05). Overall, the 3D-printed bolus resulted in reduced air gaps, dosimetry closer to prescription, and should be considered for superficial treatment areas of high irregularity.


  • Open Access

    Monte Carlo Evaluation of Dose Enhancement Due to CuATSM or GNP Uptake in Hypoxic Environments with External Beam Radiation

    by Stephen Martinez, Alexander Brandl, Del Leary

    Purpose: Most solid tumors contain areas of chronic hypoxia. Gold nanoparticles (GNP) have been extensively explored as enhancers of external beam radiation; however, GNP have lower cellular uptake in hypoxic conditions than under normoxic conditions. Conversely, the chelator diacetyl-bis (N(4)-methylthiosemicarbazonato) copper II (CuATSM) deposits copper in hypoxic regions, allowing for dose enhancement in previously inaccessible regions. Methods: External beam sources with different spectra were modeled using a Monte Carlo code (EGSnrc) to evaluate radioenhancement in a layered model with metal solutions. Also considered was a simple concentric layered tumor model containing a hypoxic core with each layer varying in concentrations of either copper or gold according to hypoxic conditions. Low energy external photon beams were then projected onto the tumor to determine the regional dose enhancement dependent on hypoxic conditions. Results: Dose enhancement was more pronounced for beam spectra with low energy photons (225 kVp) and was highly dependent on metal concentrations from 0.1 g/kg to 100 g/kg. Increasing the depth of the metallic solution layer from 1 cm to 6 cm decreased dose enhancement. A small increase in the dose enhancement factor (DEF) of 1.01 was predicted in the hypoxic regions of the tumor model with commonly used diagnostic concentrations of CuATSM. At threshold concentrations of toxic subcutaneous injection levels, the DEF increases to 1.02, and in simulation of a high concentration of CuATSM, the DEF increased to 1.07. High concentration treatments are also considered, as well as synergistic combinations of GNP/CuATSM treatments. Conclusion: The research presented is novel utilization of CuATSM to target hypoxic regions and act as a radiosensitizer by the nature of its ability to deposit copper metal in reduced tissue. We demonstrate CuATSM at high concentrations with low energy photons can increase dose deposition in hypoxic tumor regions.


  • Open Access

    Electron Scattering in Conventional Cell Flask Experiments and Dose Distribution Dependency

    by Jeremy S. Haskins, Stephen K. Martinez, Madison Engstrom, Mami Murakami, Takashi Mori, Del Leary, Takamitsu A. Kato

    Electron beam therapy (EBT) is commonly used for treating superficial and subdermal tumors. Previous cellular radiosensitivity research using EBT may be underestimating the contribution from flask wall scattering and the corresponding dose distribution. Single cell suspensions of Chinese hamster ovary (CHO) cells were plated on flasks and irradiated with 3, 4, 7, 9, and 18 MeV energy electron beams from two different institutions, and the spatial locations of surviving colonies were recorded. Gafchromic film dosimetry and Monte Carlo simulations were carried out to determine the spatial electron scattering contribution from the flask walls. Low electron irradiation resulted in an uneven surviving colony distribution concentrated near the periphery of the flasks, while spatial colony formation was statistically uniform at energies above 7 MeV. Our data demonstrates that without proper dosimetric corrections, studies using low energy electrons can lead to misinterpretations of energy dependent cellular radiosensitivity in culture vessels, and radiotherapeutic applications.